| Literature DB >> 35087585 |
Zhuqing Zhou1, Lin Chen1, Jie Liu1, Fang Ji1, Yuanyuan Shang1, Xudong Yang1, Yao Yang1, Chuangang Fu1.
Abstract
OBJECTIVE: This study was to quantitatively synthesize data in randomized controlled trials (RCTs) of laparoscopic resection comparing natural orifice specimen extraction (NOSE) versus conventional laparoscopy (CL) in colorectal cancer.Entities:
Year: 2022 PMID: 35087585 PMCID: PMC8789476 DOI: 10.1155/2022/6661651
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Flow diagram of the study search and selection process.
Characteristic of 21 studies included in the meta-analysis.
| No. | First author/year [Ref] | Country/region | Sample size | Age (years), mean ± SD or median (range) | Gender ( | BMI (kg/m2), mean ± SD or median (range) | |
|---|---|---|---|---|---|---|---|
| Male | Female | ||||||
| 1. | Yi Ding/2019 [ | China | 43/43 | 56.48 ± 10.23/58.02 ± 9.66 | 25/22 | 18/21 | 23.6 ± 3.1/.2 ± 3.4 |
| 2. | A.M. Wolthuis/2015 [ | Belgium | 20/20 | 54 (31–72)/58 (40–73) | 5/10 | 15/10 | 23.5 (18–29)/24 (20–29) |
| 3. | Zhe Zhu/2020 [ | China | 104/119 | 61.4 ± 12.3/62.5 ± 12.1 | 50/65 | 64/56 | 23.2 ± 1.6/24.4 ± 3.7 |
| 4. | A. L. H. Leung/2013 [ | Hong Kong, China | 35/35 | 62 (51–86)/72 (49–84) | 13/12 | 22/23 | - |
| 5. | Mengmeng Shen/2019 [ | China | 42/42 | 58.61 ± 4.44/58.46 ± 4.21 | 20/18 | 22/24 | 22.16 ± 0.51/22.14 ± 0.62 |
| 6. | Hongliang Gao/2020 [ | China | 54/54 | 60.67 ± 6.95/61.93 ± 7.07 | 33/31 | 21/23 | - |
| 7. | Qiang Zhao/2019 [ | China | 21/25 | 58.2 ± 7.6/50.5 ± 6.8 | 12/15 | 9/10 | 26.4 ± 7.9/27.3 ± 8.2 |
| 8. | Dongsheng Feng/2018 [ | China | 58/58 | 59.14 ± 5.97/59.09 ± 6.14 | 37/35 | 21/23 | - |
| 9. | Jin Wang/2019 [ | China | 142/131 | 60.9 ± 6.6/60.3 ± 6.4 | 75/72 | 67/59 | - |
| 10. | Haitao Ding/2017 [ | China | 60/60 | 58.33 ± 3.38/58.26 ± 3.36 | 37 | 23 | 22.88 ± 2.66/22.87 ± 2.65 |
| 11. | Kaijing Wang/2019 [ | China | 114/121 | 61.4 ± 12.3/62.5 ± 12.1 | 50 | 64 | 23.2 ± 1.6/24.4 ± 3.7 |
| 12. | Dan Zhao/2017 [ | China | 20/20 | 52.15 ± 3.50/53.05 ± 4.50 | 12/13 | 8/7 | 21.7/20.6 |
| 13. | Lei Zhao/2019 [ | China | 30/30 | 40.5 ± 3.5/43.5 ± 3.5 | 18/17 | 12/13 | 21.4/21.7 |
| 14. | Xiaohui Li/2018 [ | China | 30/30 | 53.8 ± 11.4/54.7 ± 12.2 | 16/16 | 14/14 | - |
| 15. | Mingfu Zhang/2020 [ | China | 60/60 | 58.32 ± 5.49/57.69 ± 5.12 | 36/33 | 24/27 | 23.01 ± 1.44/22.85 ± 1.21 |
| 16. | Bo Liu/2019 [ | China | 40/20 | 64.7 ± 7.6/62.8 ± 8.3 | 25/13 | 15/7 | - |
| 17. | Zudong Huang/2018 [ | China | 15/15 | 61.8 ± 8.6/62.9 ± 7.6 | 10/9 | 5/6 | - |
| 18. | Zikang Hu/2019 [ | China | 48/47 | 59.05 ± 9.98/58.87 ± 10.25 | 25/23 | 23/24 | - |
| 19. | Yewei Yue/2018 [ | China | 40/40 | 56.87 ± 10.31/58.17 ± 11.24 | 23/21 | 17/19 | 22.14 ± 1.87/21.79 ± 2.02 |
| 20. | Liya Ma/2019 [ | China | 53/53 | 54.72 ± 7.51/54.50 ± 7.32 | 28/27 | 25/26 | 23.17 ± 1.50/23.24 ± 1.35 |
| 21. | Yueyu Chen/2014 [ | China | 30/30 | 66.0 ± 1.4/67.0 ± 9.5 | 17/14 | 13/16 | - |
Note: Values are mean ± standard deviation (SD) or median (range) and “-” for not reported. Sample size, age, gender, and body mass index (BMI) data were supplied in the form of NOSES/CL separately.
Level of evidence and modified Jadad quality score for the 21 included studies.
| No. | First author/year [Ref] | Level of evidencea | Modified Jadad quality score with six itemsb | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Randomization (2) | Blinding (2) | Withdrawals and dropouts (1) | Inclusion/exclusion criteria (1) | Adverse effects (1) | Statistical analysis (1) | Total | |||
| 1. | Yi Ding/2019 [ | 1b | 1 | 0 | 1 | 1 | 0 | 1 | 4 |
| 2. | A.M. Wolthuis/2015 [ | 1b | 2 | 1 | 1 | 1 | 0 | 1 | 6 |
| 3. | Zhe Zhu/2020 [ | 1b | 1 | 0 | 1 | 1 | 1 | 1 | 5 |
| 4. | A. L. H. Leung/2013 [ | 1b | 1 | 1 | 1 | 1 | 1 | 1 | 6 |
| 5. | Mengmeng Shen/2019 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 6. | Hongliang Gao/2020 [ | 1b | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| 7. | Qiang Zhao/2019 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 8. | Dongsheng Feng/2018 [ | 1b | 1 | 0 | 0 | 0 | 1 | 1 | 3 |
| 9. | Jin Wang/2019 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 10. | Haitao Ding/2017 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 11. | Kaijing Wang/2019 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 12. | Dan Zhao/2017 [ | 1b | 1 | 0 | 1 | 1 | 1 | 1 | 5 |
| 13. | Lei Zhao/2019 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 14. | Xiaohui Li/2018 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 15. | Mingfu Zhang/2020 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 16. | Bo Liu/2019 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 17. | Zudong Huang/2018 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 18. | Zikang Hu/2019 [ | 1b | 1 | 0 | 1 | 1 | 1 | 1 | 5 |
| 19. | Yewei Yue/2018 [ | 1b | 1 | 0 | 1 | 1 | 1 | 1 | 5 |
| 20. | Liya Ma/2019 [ | 1b | 1 | 0 | 0 | 1 | 1 | 1 | 4 |
| 21. | Yueyu Chen/2014 [ | 1b | 1 | 0 | 1 | 1 | 1 | 1 | 5 |
aLevel of evidence was evaluated by using the Oxford Levels of Evidence (http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009); bthe modified Jadad scale was composed of 6 items, including the following: (i) randomization (yes scored 2 points and no scored 0), (ii) blinding (yes scored 2 and no scored 0), (iii) description of withdrawals and dropouts (yes scored 1 point and no scored 0 points), (iv) inclusion/exc1usion criteria (yes scored 1 point and no scored 0 points), (v) adverse effects (yes scored 1 and no scored 0), and (vi) statistical analysis (yes scored 1 and no scored 0).
Figure 2Funnel plot of the meta-analysis using the rate ratios against their standard errors. (a) Estimated blood loss in millilitres; (b) hospital stay after surgery in days; (c) total postoperative complications; (d) incision infection.
Intraoperative data and postoperative recovery of studies included in the meta-analysis.
| No. | First author/year [Ref] |
| Operation time (min) | Blood loss (ml) | Hospital stay after surgery (days) | Pain score (VAS/NRS) | Gas passage after surgery (days) | Cosmetic result |
|---|---|---|---|---|---|---|---|---|
| 1. | Yi Ding/2019 [ | 43/43 | 131.59 ± 26.43/123.28 ± 23.87 | 59.31 ± 14.64/75.41 ± 18.16 | 6.9 ± 3.0/7.7 ± 3.3 | 4.2 ± 1.6/5.9 ± 1.4a | 2.1 ± 1.0/2.6 ± 1.2 | 8.0 ± 1.5/6.4 ± 1.1 |
| 2. | A.M. Wolthuis/2015 [ | 20/20 | 90 (70–125)/75 (50–160) | 10 (0–100)/0 (0–250) | 4 (2–8)/4 (3–17) | 3.5/2.1a | - | 21 (14-24)/18 (8-24) |
| 3. | Zhe Zhu/2020 [ | 104/119 | 166.2 ± 42.1/147.0 ± 45.0 | 52.6 ± 23.1/91.3 ± 56.7 | 7.4 ± 2.2/10.5 ± 3.5 | 3.4 ± 1.6/8 ± 2.1a | 1.09 ± 0.51/2.02 ± 0.47 | - |
| 4. | A. L. H. Leung/2013 [ | 35/35 | 105 (60–170)/100 (59–210) | 30 (10–50)/30 (10–100) | 5 (4–9)/5 (3–11) | 1 (0–5)/2 (0–6)a | - | - |
| 5. | Mengmeng Shen/2019 [ | 42/42 | 182.61 ± 42.11/134.23 ± 28.71 | 72.45 ± 15.83/89.85 ± 18.51 | 8.42 ± 3.11/10.24 ± 4.45 | 2.08 ± 0.49/2.79 ± 0.83 | - | |
| 6. | Hongliang Gao/2020 [ | 54/54 | 123.92 ± 6.58/125.74 ± 7.67 | 88.96 ± 6.57/91.27 ± 5.55 | 7.05 ± 2.24/10.38 ± 2.19 | 2.41 ± 0.72/3.65 ± 1.05 | - | |
| 7. | Qiang Zhao/2019 [ | 21/25 | 140.6 ± 20.8/132.2 ± 16.2 | 75.5 ± 9.4/73.6 ± 7.5 | 8.3 ± 1.2/10.8 ± 1.5 | 4.2 ± 0.8/5.5 ± 0.9b | 3.2 ± 0.3/4.5 ± 0.6 | - |
| 8. | Dongsheng Feng/2018 [ | 58/58 | 122.95 ± 6.95/126.97 ± 6.75 | 89.98 ± 6.58/92.06 ± 5.74 | 7.04 ± 2.32/10.37 ± 2.43 | - | 2.42 ± 0.75/3.64 ± 1.03 | - |
| 9. | Jin Wang/2019 [ | 142/131 | - | - | - | - | - | - |
| 10. | Haitao Ding/2017 [ | 60/60 | 124.06 ± 5.48/125.33 ± 5.54 | 91.08 ± 4.53/89.65 ± 5.54 | 10.43 ± 1.12/7.76 ± 1.05 | 3.86 ± 0.60/2.61 ± 0.59b | 3.58 ± 0.61/2.54 ± 0.52 | - |
| 11. | Kaijing Wang/2019 [ | 114/121 | 167.0 ± 45.0/146.2 ± 42.1 | 52.6 ± 23.1/91.3 ± 75.1 | 11.7 ± 3.1/18.1 ± 4.2 | - | 0.67 ± 0.25/1.04 ± 0.26 | - |
| 12. | Dan Zhao/2017 [ | 20/20 | 180.6 ± 25.8/150 ± 14.4 | 69.25 ± 6.13/85.75 ± 7.60 | 8.25 ± 1.02/8.95 ± 1.85 | - | - | - |
| 13. | Lei Zhao/2019 [ | 30/30 | 187.2 ± 25.2/153 ± 14.4 | 69.36 ± 6.18/85.66 ± 7.71 | 8.27 ± 1.04/8.92 ± 1.82 | - | - | - |
| 14. | Xiaohui Li/2018 [ | 30/30 | - | - | 5.3 ± 1.5/8.5 ± 1.6 | - | 1.01 ± 0.14/1.50 ± 0.17 | - |
| 15. | Mingfu Zhang/2020 [ | 60/60 | 129.32 ± 15.21/125.04 ± 12.28 | 80.23 ± 10.85/89.95 ± 16.43 | 7.02 ± 1.13/8.89 ± 2.16 | - | 2.02 ± 0.51/2.89 ± 0.73 | - |
| 16. | Bo Liu/2019 [ | 40/20 | 186.4 ± 17.9/169.8 ± 18.3 | 78.25 ± 11.3/82.5 ± 11.2 | 10.8 ± 3.06/13.5 ± 1.8 | 4.3 ± 1.12/7.1 ± 0.9b | 2.48 ± 0.64/2.35 ± 0.58 | - |
| 17. | Zudong Huang/2018 [ | 15/15 | 145.39 ± 39.61/123.94 ± 45.37 | 30.27 ± 10.00/25.47 ± 5.00 | 5.78 ± 2.13/9.43 ± 1.83 | - | 1.84 ± 0.78/1.76 ± 0.64 | - |
| 18. | Zikang Hu/2019 [ | 47/48 | - | 50.54 ± 7.34/67.86 ± 9.25 | 12.86 ± 3.56/16.11 ± 3.98 | - | 2.12 ± 1.04/3.49 ± 1.37 | - |
| 19. | Yewei Yue/2018 [ | 40/40 | 159.73 ± 21.49/150.18 ± 20.39 | 42.08 ± 12.28/48.98 ± 13.35 | 9.11 ± 3.26/12.27 ± 3.45 | - | 2.07 ± 0.53/2.68 ± 0.72 | - |
| 20. | Liya Ma/2019 [ | 53/53 | 184.72 ± 42.35/228.18 ± 45.03 | 114.42 ± 38.40/132.46 ± 44.64 | 7.81 ± 1.55/9.04 ± 2.47 | - | 3.01 ± 1.05/3.88 ± 1.26 | - |
| 21. | Yueyu Chen/2014 [ | 30/30 | 118.5 ± 22.0/138.1 ± 23.8 | - | 8.0 ± 2.8/11.0 ± 3.5 | - | 3.40 ± 0.23/3.59 ± 0.36 | - |
Note: Values are mean ± standard deviation (SD) or median (range); “-” for data not reported; data are supplied in the form of NOSES/CL separately. aPain score using VAS; bpain score using NRS.
Figure 3Forest plots of intraoperative data and postoperative recovery between the NOSE group and the CL group. (a) Operation time in minutes; (b) estimated blood loss in millilitres; (c) hospital stay after surgery in days; (d) pain score; (e) gas passage after surgery in days; (f) cosmetic result.
Postoperative complications of studies included in the meta-analysis.
| No. | First author/year [Ref] |
| Anastomotic leakage | Ileus | Incision bleeding | Urinary retention | Infectiona | Other complications | Total |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Yi Ding/2019 [ | 43/43 | 1/0 | 1/1 | - | - | 1/3 | 1/1 | 4/5 |
| 2. | A.M. Wolthuis/2015 [ | 20/20 | 0/1 | - | - | - | 0/1 | 3/1 | 3/3 |
| 3. | Zhe Zhu/2020 [ | 104/119 | 2/2 | - | - | - | 7/15 | 3/3 | 12/20 |
| 4. | A. L. H. Leung/2013 [ | 35/35 | 0/0 | - | - | - | 0/4 | - | 0/4 |
| 5. | Mengmeng Shen/2019 [ | 42/42 | 1/1 | 1/1 | - | 1/0 | 1/2 | - | 4/4 |
| 6. | Hongliang Gao/2020 [ | 54/54 | - | - | - | - | - | - | - |
| 7. | Qiang Zhao/2019 [ | 21/25 | 1/0 | 1/0 | - | - | 0/1 | - | 2/1 |
| 8. | Dongsheng Feng/2018 [ | 58/58 | - | - | - | - | - | - | - |
| 9. | Jin Wang/2019 [ | 142/131 | - | - | - | - | 3/10 | 8/15 | 11/25 |
| 10. | Haitao Ding/2017 [ | 60/60 | - | - | - | - | - | - | - |
| 11. | Kaijing Wang/2019 [ | 114/121 | 8/11 | - | - | - | 1/6 | 3/3 | 12/20 |
| 12. | Dan Zhao/2017 [ | 20/20 | 0/0 | - | 0/0 | - | - | - | 0/0 |
| 13. | Lei Zhao/2019 [ | 30/30 | - | - | 1/2 | - | - | 0/1 | 1/3 |
| 14. | Xiaohui Li/2018 [ | 30/30 | - | - | - | - | 1/8 | 2/3 | 3/11 |
| 15. | Mingfu Zhang/2020 [ | 60/60 | - | 0/1 | 0/1 | - | 0/2 | 1/0 | 1/4 |
| 16. | Bo Liu/2019 [ | 40/20 | 6/2 | - | - | 13/2 | 0/6 | 16/9 | 35/19 |
| 17. | Zudong Huang/2018 [ | 15/15 | - | - | 1/3 | - | 1/2 | - | 2/5 |
| 18. | Zikang Hu/2019 [ | 47/48 | - | - | 4/3 | - | 1/8 | 2/1 | 7/12 |
| 19. | Yewei Yue/2018 [ | 40/40 | - | - | - | 0/1 | 3/3 | 0/2 | 3/6 |
| 20. | Liya Ma/2019 [ | 53/53 | - | 0/3 | - | 0/3 | - | - | 0/6 |
| 21. | Yueyu Chen/2014 [ | 30/30 | - | - | - | - | 2/6 | - | 2/6 |
Note: “-” indicated data not reported; data are supplied in the form of NOSES/CL separately; aspecific postoperative infection data are presented in Table 5.
Postoperative infection of studies included in the meta-analysis.
| No. | First author/year [Ref] |
| Incision infection | Pulmonary infection | Intraperitoneal infection | Urinary tract infection | Subtotal |
|---|---|---|---|---|---|---|---|
| 1. | Yi Ding/2019 [ | 43/43 | 0/2 | 1/1 | 0/0 | - | 1/3 |
| 2. | A.M. Wolthuis/2015 [ | 20/20 | - | - | - | 0/1 | 0/1 |
| 3. | Zhe Zhu/2020 [ | 104/119 | 0/5 | 6/9 | 1/1 | - | 7/15 |
| 4. | A. L. H. Leung/2013 [ | 35/35 | 0/4 | - | - | - | 0/4 |
| 5. | Mengmeng Shen/2019 [ | 42/42 | 1/2 | - | - | - | 1/2 |
| 6. | Hongliang Gao/2020 [ | 54/54 | - | - | - | - | - |
| 7. | Qiang Zhao/2019 [ | 21/25 | 0/1 | - | - | - | 0/1 |
| 8. | Dongsheng Feng/2018 [ | 58/58 | - | - | - | - | - |
| 9. | Jin Wang/2019 [ | 142/131 | - | 2/7 | - | 1/3 | 3/10 |
| 10. | Haitao Ding/2017 [ | 60/60 | - | - | - | - | - |
| 11. | Kaijing Wang/2019 [ | 114/121 | 0/5 | - | - | 1/1 | 1/6 |
| 12. | Dan Zhao/2017 [ | 20/20 | - | - | - | - | - |
| 13. | Lei Zhao/2019 [ | 30/30 | - | - | - | - | - |
| 14. | Xiaohui Li/2018 [ | 30/30 | 0/6 | 0/1 | - | 1/1 | 1/8 |
| 15. | Mingfu Zhang/2020 [ | 60/60 | 0/2 | - | - | - | 0/2 |
| 16. | Bo Liu/2019 [ | 40/20 | 0/6 | - | - | - | 0/6 |
| 17. | Zudong Huang/2018 [ | 15/15 | 1/2 | - | - | - | 1/2 |
| 18. | Zikang Hu/2019 [ | 47/48 | 1/8 | - | - | - | 1/8 |
| 19. | Yewei Yue/2018 [ | 40/40 | 2/1 | 1/2 | - | - | 3/3 |
| 20. | Liya Ma/2019 [ | 53/53 | - | - | - | - | - |
| 21. | Yueyu Chen/2014 [ | 30/30 | 1/1 | 0/4 | - | 1/1 | 2/6 |
Note: “-” indicated data not reported; data are supplied in the form of NOSES/CL separately.
Figure 4Forest plots of postoperative complications between the NOSE group and the CL group. (a) Anastomotic leakage; (b) ileus; (c) incision bleeding; (d) urinary retention; (e) other complications; (f) infection; (g) total complications; (h) incision infection.
Recurrence and overall survival of studies included in the meta-analysis.
| No. | First author/year [Ref] | Patients, | Duration of follow-up, months | Recurrence, | Overall survival, |
|---|---|---|---|---|---|
| 1. | Yi Ding/2019 [ | 43/43 | (12-45)/(12-45) | 3/1 | - |
| 2. | Mingfu Zhang/2020 [ | 60/60 | (12-24)/(12-24) | 0 | - |
| 3. | Zikang Hu/2019 [ | 47/48 | 24/24 | 12/11 | 35/35 |
| 4. | Yewei Yue/2018 [ | 40/40 | 24/24 | 8/9 | 34/30 |
| 5. | Yueyu Chen/2019 [ | 30/30 | 28 (3-48)/28 (3-48) | 0/0 | - |
Note: -: not reported. Data are supplied in the NOSES/CL form.
Figure 5Forest plots of recurrence and overall survival rate between the NOSE group and the CL group. (a) Disease recurrence rate; (b) overall survival rate.